As previously reported, UBS analyst Fatima Boolani downgraded Symantec to Neutral from Buy on a more balanced risk/reward. The analyst said the consensus bullish view of earnings and growth expectations is already priced into the stock. Boolani raised her price target to $33 from $31 on Symantec shares.

KeyBanc analyst Chris O'Cull downgraded Jack in the Box to Sector Weight saying the Qdoba announcement overshadowed what was otherwise disappointing quarterly report. The analyst is concerned with Jack in the Box SRS performance and the competitive environment and expects sluggish topline performance to continue for both brands over the next several quarters. O'Cull lowered his FY18 earnings and cash flow estimates to reflect reduced sales and profit expectations and views shares as fairly valued.

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Ultragenyx (RARE) was downgraded to Neutral from Buy at H.C. Wainwright and to Neutral from Outperform at Wedbush. 2. Grainger (GWW) downgraded to Underperform on pricing risks at Credit Suisse with analyst Andrew Buscaglia telling investors he sees more uncertainty around its pricing strategy for its highest margin mid-sized customers and continued gross margin declines in 2018 that will weigh on shares. Buscaglia believes Grainger is the most susceptible to the Amazon (AMZN) threat as evidenced by its pricing actions to its more profitable smaller-medium sized customers and said its move online makes it more susceptible to competitive pricing. 3. Interactive Brokers (IBKR) downgraded to Market Perform at Keefe Bruyette with analyst Kyle Voigt citing the company's first quarter results. 4. Regions Financial (RF) downgraded to In Line from Outperform at Evercore ISI with analyst John Pancari citing limit upside to valuation given mounting earnings headwinds. 5. Sirius XM (SIRI) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Benjamin Swinburne telling investors the business is maturing and growth is slowing. Swinburne said Sirius is executing well, but the benefit from new car turnover has likely peaked and not longer adds material to the subscription base, and adds used car growth has also peaked. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

William Blair analyst Ryan Merkel downgraded Grainger to Market Perform citing a lack of confidence in the company's repricing strategy.

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Disney (DIS) downgraded to Hold from Buy at Loop Capital with analyst David Miller citing valuation following the stock hitting a 52-week high on Friday. The strength in the stock over the last nine months has appropriately priced in the company's growth rate, said Miller, who maintains a $118 price target on Disney shares. 2. Groupon (GRPN) downgraded to Underweight on lackluster ad spend at Morgan Stanley with analyst Brian Nowak saying its recent local advertiser survey indicate lackluster forward advertiser spending and believes Groupon will need to spend more in order to grow North America Local Billings, which the Street seems to be underestimating. 3. Grainger (GWW) downgraded to Market Perform from Outperform at William Blair with analyst Ryan Merkel citing a lack of confidence in the company's repricing strategy. 4. Bank of America (BAC) downgraded to Hold from Buy at Berenberg with analyst James Chappell saying it is time to take profits. Interest rates unlikely to rise as much as has been priced into bank equity valuations, Chappell tells investors in a research note. Further, regulation and tax reform are likely to take longer than expected and not be as beneficial for the banks as many might have hoped, the analyst adds. He upped his price target for Bank of America shares to $22 from $15. 5. DuPont Fabros (DFT) downgraded to Hold from Buy at Stifel with analyst Matthew Heinz saying shares are fully valued and demand patterns have shifted. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

Deutsche Bank analyst John Inch downgraded Grainger to Sell and cut his price target for the shares to $145 from $246. The company is "positioned to quickly lose share" as competitors respond with price cuts of their own, Inch tells investors in a research note. He does not expect Grainger to realize sustained volume improvement to offset the negative impact of its price cuts.

Needham analyst James Ricchiuti downgraded Stratasys to Hold from Buy citing the recent "sharp" rise in the shares despite only a "modest" improvement in the company's fundamentals. While Stratasys could see stronger growth next year, the timing of additive manufacturing deployments is uncertain and the general purpose prototyping business is becoming an increasingly mature market, Ricchiuti tells investors.

William Blair analyst Brian Drab downgraded Stratasys to Underperform from Market Perform with the shares up 43% in the last month and 81% year-to-date. The stock is overvalued at $30, Drab tells investors in a research note. This price represents a 100 times multiple on the consensus 2017 adjusted earnings estimate and 57 times multiple on the 2018 consensus estimate, the analyst points out. He says the current valuation "reflects expectations for a return to robust growth and material margin expansion, both of which are unlikely."

Jefferies analyst James Kisner downgraded Stratasys to Hold citing the recent rally in the shares and uncertainty around the timing of new manufacturing opportunities. The analyst raised his price target for the stock to $30 from $24 following the company's Q1 results.

Stephens analyst Chris Cooley downgraded Endologix to Equal Weight from Overweight after the company announced that its Nellix plans are delayed again and it will now seek U.S. approval of the Nellix EVAS System by conducting a confirmatory clinical study with its Gen2 device design. Cooley cut his price target on Endologix shares to $6 from $10.

Oppenheimer analyst Steven Lichtman downgraded Endologix to Perform and lowered his price target for the shares to $5.50 from $10. The downgrade follows the company's announcement that it willseek U.S. approval of the Nellix EVAS System by conducting a confirmatory clinical study. BTIG and Stifel this morning also downgraded Endologix.

As noted earlier, BTIG downgraded Endologix to Neutral from Buy. Analyst Sean Lavin downgraded the stock after the company announced that following its meeting with the FDA it will not seek approval of its first generation Nelix device and will instead seek approval of its second generation Nelix device. Lavin notes that an additional clinical trial will have to be performed on the second generation device before it can be approved. He does not expect the device to reach the U.S. market until 2020. Target $7.

As noted earlier, Stifel downgraded Endologix to Hold from Buy. Analyst Mathew Blackman downgraded the stock after the company announced that after meeting with the FDA it will not seek approval of its first generation Nelix device and will instead seek approval of its second generation Nelix device. Blackman notes that an additional clinical trial will have to be performed on the second generation device before it can be approved. He does not expect it to be approved until 2020 at the earliest. Target to $5.50 from $10.